Astrazeneca Pharma India: A Promising Investment Opportunity in the Pharma Industry

Astrazeneca Pharma India, a midcap pharmaceutical company, has been making headlines in the stock market recently. The company's stock has been underperforming the sector by -13.55% and has been on a consecutive fall for the last 3 days, with a -17.9% decline in returns during this period. Today, the stock opened with a loss of -8.74%, touching an intraday low of Rs 5615.95 (-14.59%).

Despite these recent dips, Astrazeneca Pharma India's stock is still performing well in the long term. It is currently higher than its 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, it is lower than its 5-day and 20-day moving averages, which could be a cause for concern for short-term investors.

In comparison to the Sensex, Astrazeneca Pharma India's stock has seen a -13.11% decline in the last 1 day, while the Sensex has only seen a 0.05% change. However, in the last 1 month, the stock has outperformed the Sensex with a 1.25% increase, while the Sensex has only seen a 0.11% change.

Overall, Astrazeneca Pharma India's stock is currently a 'Buy' according to MarketsMOJO, and it has been a part of MOJO Stocks on MarketsMOJO since 2023-08-29. With its strong performance in the long term and potential for growth in the future, Astrazeneca Pharma India is a promising investment opportunity in the pharma industry.